Background and aims Pharmacotherapy can be an important part of the continuum of care for alcohol use disorder
INTRODUCTION
Alcohol use disorder (AUD) is a chronic health problem [1, 2] , with most individuals benefiting from several treatment episodes before achieving long-term remission [3] . Pharmacotherapies and medication-assisted therapy (combining pharmacotherapy with psychotherapy) can be an important part of the continuum of care for AUD. Several approved medications can reduce the risk of relapse [4, 5] .
Despite evidence of effectiveness of pharmacotherapy for treatment of AUD, many studies have reported significant barriers to implementation of pharmacotherapy, with salient challenges emerging at the health system, organizational and provider levels in the United States [6] . In addition to studies identifying training and experience of providers as barriers to use of AUD pharmacotherapies [6] [7] [8] [9] , US providers have also expressed concerns about prescription prices [10, 11] and time constraints [6, 11] as barriers to prescribing AUD pharmacotherapies. There are also patient-level barriers to adoption of pharmacotherapy, but relatively few studies have focused on this issue [6] and findings are mixed [12] . Regarding socio-economic status (SES), Knudsen and colleagues [10] noted that providers thought their patients (in this case, clients at publically funded US treatment programs) would be interested in, but unable to afford, pharmacotherapies for substance use disorders (SUD). Patients in a small US focus group study discussed price and medication availability as barriers to using oral naltrexone for AUD [11] . In the United States and other countries, such as Sweden, cost concerns may be less relevant, as pharmacotherapies are already or will become more affordable and more widely available.
There may be differences in physicians' prescribing practices that influence adoption of pharmacotherapies for AUD by different population subgroups. Relatively little research has examined this question in the general population, however. A study of dually diagnosed US veterans found that approximately 70% received psychiatric pharmacotherapies, but only 10% received AUD pharmacotherapies [13] , which suggests that there may be aspects of physicians' prescribing practices unique to AUD pharmacotherapies. It is unknown whether and to what extent patient characteristics influence physicians' behaviors regarding prescription of AUD pharmacotherapies, but studies of other health conditions such as cardiovascular disease [14] and diabetes [15] suggest that there may be substantial differences by patient SES in receipt of appropriate pharmacotherapies.
Once they have been prescribed, most of these medications require one or more pills to be taken daily to treat AUD. One study, conducted in a large US health plan [16] found that most patients used oral naltrexone for a much shorter period than recommended; data from the US Veterans Administration [17] found that the typical treatment episode for disulfiram or oral naltrexone was also shorter than recommended. Another large US study using prescription data provided by insurance companies also found that the majority of users of oral naltrexone filled only one or two prescriptions during a 6-month period [18] . Patients who filled prescriptions consistently were older, less likely to have received prior treatment for AUD and lived in higher SES areas [18] . An Australian study using national pharmaceutical benefits claims data found that men and patients under age 25 were less likely than their peers to fill multiple prescriptions for AUD pharmacotherapies [19] . Other studies have detected lower rates of adherence to various pharmacotherapies by patients with comorbid psychiatric or drug use disorders [12] as well as by lower-income patients, older adults and women [20] . To build upon these prior studies, the current project uses data from population registries in Sweden to examine pharmacotherapy use in a cohort of people with AUD.
Despite public financing for health care that reaches everyone, there are socio-economic disparities in health outcomes in Sweden. For example, neighborhood deprivation is associated with increased risk of diabetes [21] , heart disease [22, 23] and children's psychiatric disorders [24] . The Swedish universal health-care system emphasizes provision of care to marginalized groups, and most treatment for substance use disorders is supported by public funds [25] . Even in this supportive policy context there are disparities in drug outcomes by neighborhood deprivation [26] [27] [28] , as well as disparities in alcohol outcomes by level of education [29] and immigrant status [30] . In Sweden, however, disparities by neighborhood SES are unlikely to be driven by restricted access to appropriate health care [31] . One Swedish national study documented that high-and moderate-deprivation neighborhoods actually had greater access to health-care resources such as pharmacies, hospitals and clinics than low-deprivation neighborhoods [31] . In the aforementioned US study using insurance data [18] , higher area-level SES was associated with significantly higher persistence with oral naltrexone. It remains to be examined whether neighborhood or other socio-economic differences in AUD pharmacotherapy would exist in Sweden.
Using data from a large national cohort of Swedish AUD patients, we investigated whether disparities in pharmacotherapy exist in the context of universal health care. Our primary research question was: are there differences in filling prescriptions for AUD pharmacotherapies according to neighborhood deprivation or other indicators of disadvantaged social status? Based upon prior research [18] , we hypothesized that AUD patients who are residents of deprived neighborhoods would be less likely to fill a prescription for pharmacotherapy than their counterparts living in more affluent neighborhoods. We also expected to see disparities for individuals with low SES [10, 11, 14, 18] and for foreignborn residents [30] .
METHODS

Design
We used a longitudinal design to follow an open cohort of Swedish people who received either in-patient (hospital) or out-patient care for AUD during a 7-year period to assess relationships of neighborhood deprivation and patient demographic characteristics with filling prescriptions for AUD pharmacotherapy.
Data
To define the cohort, we extracted data from several linked national Swedish population-based registers. Each person in Sweden has a unique 10-digit identification number; this was replaced by a de-identified serial number in order to preserve anonymity while permitting registry linkages. More detail on the registers is provided below. The Regional Ethical Review Board for Lund University granted approval for this study.
Cohort definition
Based on alcohol-related International Classification of Disease (ICD-10) codes [32] , cases of AUD registered between July 2005 and June 2012 were identified using all hospitalizations in the Swedish Hospital Discharge Register and all clinic/office visits in the Outpatient Care Register. Both of these registries are nationally inclusive. The relevant ICD-10 codes included both alcohol abuse (F10, excluding acute alcohol intoxication, F10.0) and alcohol-related somatic diagnoses (E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K70.0-K70.9, K85.2, K86.0, O35.4 and T51.0-T51.9). We identified 62 549 individuals with AUD during the study period.
Measures
Outcomes
Receipt of pharmacotherapy was based on the Swedish Prescribed Drug Register to identify all prescriptions for disulfiram, naltrexone, acamprosate and nalmefene picked up by patients in the AUD cohort between 2005 and 2012. The primary outcome was ever picking up a prescription for one or more AUD pharmacotherapies (versus not).
An important question is whether findings represent physician differences in prescribing pharmacotherapy according to levels of neighborhood deprivation or patient characteristics, or whether findings illustrate reduced prescription compliance by socially disadvantaged patients. Using data from the Primary Healthcare Registers for 75 primary health-care centres in mid-West Sweden between July 2005 and December 2007 we ascertained a secondary outcome, prescription compliance, which was defined as picking up a pharmacotherapy prescription known to have been issued in primary care. As a validity check, we ascertained this secondary outcome for a subsample of 1186 patients from the AUD cohort who were prescribed one or more of the pharmacotherapies at a primary care visit during the study period.
Predictors
Neighborhood deprivation was calculated for geographic areas defined by the Swedish government statistics bureau, Statistics Sweden, known as SAMS (small areas for market statistics). SAMS boundaries are defined by natural borders such as rivers or highways, and they often contain homogeneous building types; the average population is approximately 1000 residents. Small geographic areas are consistent with how people define their neighborhoods [33] . More than 97% of the population can be geocoded to a SAMS. Neighborhood deprivation was defined using aggregated data from the Total Population Register. The neighborhood measure included data for all residents aged 25-64 years, as these working-age residents are key to defining an area's SES. As in prior studies [26, 31, 34] , indicators included the proportions of residents with fewer than 10 years of education, incomes less than half the national median, unemployed residents and individuals on financial assistance. Neighborhood deprivation for the SAMS of residence in 2005 was classified into three groups based on the national population mean and standard deviation (SD). Low deprivation (most affluent) was below 1 SD from the mean (analytical referent); moderate deprivation was within 1 SD of the mean; and high deprivation (most deprived) was above 1 SD from the mean, as in previous studies [34] . In our cohort of AUD patients, only 14.6% were in the low neighborhood deprivation group and 25.7% were in the high deprivation group. A large majority of AUD patients (90.0%) stayed in a neighborhood of the same level of deprivation between 2005 and 2006; neighborhood deprivation was not available after this point.
Other indicators of disadvantaged social status were also drawn from the Total Population Register. We included family income in 2005 (categorized into quartiles, with highest income as the referent), highest level of education [three groups: compulsory high school or less (< 10 years), practical high school or some theoretical high school (10-11 years), theoretical high school completion and college or post-graduate study (≥ 12 years)] and country of origin (Sweden versus foreign-born).
Covariates
Individual-level demographics drawn from the Total Population Register were age (by decade, from 30-39 to 60+ years, with < 30 as referent) and gender (male as referent). Additional covariates were drawn from the Hospital Discharge and Outpatient Registers. Comorbid drug use disorders (DUD) were based on ICD-10 codes for mental and behavioral disorders due to the use of psychoactive substances other than alcohol or tobacco (F11-F16; F18-F19). Comorbid mental health/psychiatric disorders were based on ICD-10 codes for mental, behavioral and neurodevelopmental disorders, mood disorders and anxiety/stress-related disorders, among others (F20-F99). The number of AUD registrations in the Hospital Inpatient and Outpatient Registers (one versus two and three or more registrations during study period) was included as an indicator of severity [35] .
Analyses
We used unadjusted and multivariable alternating logistic regression models to assess relationships between neighborhood deprivation and pharmacotherapy. Only 35% of neighborhoods contained more than eight individuals with AUD, so multi-level analysis strategies were not appropriate. We also chose not to use multi-level models because the second-level residuals were not distributed normally. Alternating logistic regression accounts for the dependence of cases within neighborhoods when estimating regression coefficients, and it also provides the pairwise odds ratio (PWOR), an indicator of neighborhood differences that are not accounted for by deprivation or other common unmeasured environmental factors [36] . The PWOR represents the increase in the odds of filling a pharmacotherapy prescription for AUD, given that another AUD patient selected randomly from the same neighborhood also fills a prescription; it is higher than 1.0 if picking up prescribed pharmacotherapy within a given neighborhood were more frequent than would be expected under random distribution across neighborhoods.
In sensitivity analyses, we generated additional adjusted models, with the first using only cases with incident AUD during the study period (thus excluding all cases with an AUD registration prior to 1 July 2005), because newly diagnosed patients may have higher adherence to pharmacotherapy [18] , and the second used only cases without co-occurring DUD, because naltrexone is used for treatment of opioid dependence as well as AUD [5] . Finally, we assessed associations between neighborhood deprivation and other indicators of disadvantaged social status with picking up prescriptions for each of the pharmacotherapies separately.
RESULTS
During the study period, 53.7% of AUD patients picked up pharmacotherapy prescriptions. Of those, 25.1% only picked up one prescription, 16.0% picked up two prescriptions and 58.9% picked up three or more prescriptions. Patients' first pharmacotherapy prescriptions were split between disulfiram (30.0%), naltrexone (31%) and acamprosate (38%), with nalmefene at fewer than 1%. A large proportion (44.4%) of patients who picked up a prescription did so for more than one medication; 68.0% of these patients picked up at least one prescription for disulfiram during the study period compared to 48.7% for acamprosate and 39.7% for naltrexone. Patient characteristics associated with filling a prescription are in Table 1 .
Adjusted models (Table 2) revealed that people with AUD who were living in neighborhoods with moderate or high levels of deprivation were significantly less likely to pick up pharmacotherapy prescriptions than their counterparts in affluent neighborhoods. In this cohort of AUD patients, people with lower incomes (compared to those in the highest income quartile), those with less education (compared to those with 12+ years), foreignborn patients and women also were significantly less likely to pick up prescriptions. Additionally, older patients, patients with a greater number of AUD registrations and those with co-occurring psychiatric diagnoses were significantly more likely to pick up pharmacotherapy prescriptions. The PWOR indicates that picking up prescribed pharmacotherapy within a given neighborhood was significantly more frequent than would be expected under random distribution across neighborhoods. In the validity check using data from primary care, a total of 1890 prescriptions were issued to AUD patients, and 1569 were picked up (83% compliance rate). Most indicators of disadvantaged social status (neighborhood deprivation, income, education, country of origin) were not related significantly to prescription compliance (Table 3) , although those in the lowest income quartile were significantly less likely to pick up an issued prescription for AUD pharmacotherapy than patients in the highest income quartile. Women were also significantly less likely than men to pick up AUD pharmacotherapy prescriptions issued in primary care.
When analyses were limited to individuals with incident AUD (Supporting information, Table S1 ) or without a known history of DUD (Supporting information, Table S2 ), results were very similar to the overall findings. Supporting information, Table S3 shows regression models for each medication separately; findings for neighborhood deprivation were consistent for acamprosate and naltrexone. However, people with AUD living in neighborhoods with moderate levels of deprivation were significantly more likely to pick up prescriptions for disulfiram than those in affluent neighborhoods. Patterns for other indicators of disadvantaged social status were consistent across the three pharmacotherapies.
DISCUSSION
In this cohort of patients receiving either in-patient or outpatient care for AUD, approximately half picked up a pharmacotherapy prescription during the study period. There were significant differences in picking up pharmacotherapy prescriptions by neighborhood deprivation, with those in moderately deprived Pharmacotherapy for alcohol use disorder (AUD) includes naltrexone, disulfiram, acamprosate and nalmefene. OR = odds ratio; CI = confidence interval; PWOR = pairwise odds ratio from alternating logistic regression, reflects differences between neighborhoods.
neighborhoods showing approximately 10% reduction in the odds, and those in highly deprived neighborhoods showing approximately 25% reduction in the odds, compared to those in low-deprivation neighborhoods.
(Given the high prevalence of picking up pharmacotherapy prescriptions, the odds ratios presented in this study may overestimate the relative risk.) The pattern of results was consistent for incident AUD cases, as well as for the subgroup of AUD patients without comorbid drug problems. These results for Sweden are similar to earlier findings from the United States [18] . By contrast, there was not strong evidence of socio-economic disparities in prescription compliance in the subgroup of AUD patients who were issued prescriptions in primary care. Results from this subgroup analysis suggest that factors other than patient compliance may be driving disparities in picking up prescriptions for AUD pharmacotherapies. In addition to disparities by neighborhood deprivation, we observed lower rates of picking up prescriptions for AUD pharmacotherapy for patients with lower (versus the highest) SES (indexed by both income and education). Budhiraja & Landberg [29] observed significant increases in alcohol-related mortality for Swedes with fewer than 10 years of education, with relatively little difference between those with intermediate education and those with college education. Disparities in AUD pharmacotherapies could contribute to long-term disparities in alcohol-related mortality among socially disadvantaged groups.
Lower rates of pharmacotherapy for foreign-born (compared to Swedish-born) AUD patients may be due to a variety of factors, including lower integration with primary or specialty/psychiatric care [37] , as well as communication challenges that may reduce the likelihood that a physician would initiate the detailed discussions that should accompany prescription of AUD pharmacotherapy [5] . There may also be unique barriers to using AUD pharmacotherapy by foreign-born (or other ethnic minority) patients, such as distrust of health-care providers [38] , and this deserves further study.
Women were less likely to pick up pharmacotherapy prescriptions in the full data set, as well as in the subset of primary care cases to whom we know prescriptions were issued. These findings differ somewhat from those of an Australian study, in which men were less likely than women to pick up more than one naltrexone prescription to treat AUD [19] . Further research should investigate whether AUD is more stigmatizing for women than for men in Sweden.
Older patients, those with more AUD registrations (especially those with three or more in-patient or outpatient care episodes during the study period) and those with co-occurring psychiatric diagnoses were significantly more likely to receive AUD pharmacotherapy. Morley and colleagues [19] also found that older Australians were more likely than younger patients to return for a second AUD pharmacotherapy prescription, and Kranzler and colleagues [18] found a similar pattern for naltrexone prescriptions picked up in the United States. In a study of 12 000 Swedes assessed for SUD between 2002 and 2008, Grahn and colleagues [1] found that patients with psychiatric comorbidities reported a significantly greater number of voluntary treatment episodes. Our findings suggest that physicians may be prescribing AUD pharmacotherapies to help patients with non-remitting alcohol problems who may not be served sufficiently by other treatment modalities [11] . Physicians also may prescribe AUD pharmacotherapy in concert with pharmacotherapies for other complicated psychiatric comorbidities [39] , although we did not assess this here.
In one US study [9] , in a subset of sampled alcohol and drug treatment programs that used pharmacotherapies for either substance use disorders or psychiatric conditions, average rates of adoption of AUD pharmacotherapy were quite low (approximately 24%), which was in stark contrast to medication prescribing practices for psychiatric conditions (approximately 70%). It also was lower than rates of DUD pharmacotherapy (approximately 34%) at the same facilities [9] . In the present Swedish study, the rates of AUD pharmacotherapy were much higher than data suggest may be the case for the United States, and detailed examination of Swedish health-care system factors that promote the use of AUD pharmacotherapy may help to improve care delivery in other national contexts. For example, medication cost may not be a salient issue for Swedish AUD patients, as financial assistance and cost caps (SEK2200 or US$240/month maximum) help to keep the patient burden lower than in the United States [40] . Furthermore, the health-care system is designed so there are qualified prescribers in all geographic regions of Sweden [40] ; in the United States and other countries there are geographic disparities in availability of qualified AUD treatment providers [7, 41] . One limitation is that we do not have nationally inclusive data on prescriptions issued in the in-patient or out-patient care settings. Thus, it is not clear whether our findings represent differences in prescribing practices, differences in patient compliance or both. When we linked the prescription registry data with information from primary health-care providers in a smaller geographic area we found high patient compliance, as more than 80% of issued prescriptions were picked up. This suggests that geographic and socio-economic variability in pharmacotherapy may, at least in part, reflect differences in prescribing practices.
There are some limitations pertaining to measurement of the outcome and exposure variable, as well as our case ascertainment definition. Regarding the outcome, nalmefene was approved in Europe for treatment of AUD in 2013, and our study period ended in 2012. Thus, the few AUD patients who received nalmefene are likely to have been receiving treatment for a comorbid DUD. The number of cases receiving nalmefene was very small (< 1% of all prescriptions), so findings are driven by the other pharmacotherapies. Future studies will be informative regarding the use of nalmefene for AUD treatment in Sweden. Also, neighborhood deprivation and individual SES were measured at the beginning of the study period, and they may have changed by the time that someone received either in-patient or out-patient treatment for AUD or when they received their first (or subsequent) pharmacotherapy prescriptions. Unfortunately, we do not have neighborhood data available after this point, which is a limitation of the present analyses. Our data suggest that dramatic changes in neighborhood SES are not common in Sweden, however. Finally, given our case definition of AUD, these findings represent patients with more severe AUD who have developed physical health problems due to prolonged heavy drinking. Future research should examine whether physical health problems are related to prescriptions for and adherence to AUD pharmacotherapies, as some medications are contraindicated for patients with severe hepatic issues (although others are not) [5] .
There are many benefits that accrue from AUD pharmacotherapy [18, 42] . Future research should determine whether long-term benefits are conferred equally across population subgroups or whether disparities in alcohol outcomes widen due to a mismatch between clinical need and pharmacotherapies received by patients [43] . Interventions with physicians and other health-care providers who can prescribe medications may help to increase the use of pharmacotherapy as part of the AUD treatment regimen. Targeting these interventions and other forms of outreach to clinics in deprived neighborhoods and to those that serve women and foreign-born residents may help to prevent relapse and reduce the burden of AUD among disadvantaged population subgroups in Sweden.
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